Boeing's 737 Max Aircraft Production Suspension To Aid Airbus

The year 2019, which has already been a controversial year for Boeing (NYSE:BA) , seems to end on a dismal note for the aircraft manufacturing giant, with the recent announcement of its decision to temporarily suspend the production of 737 Max jetliner, beginning January 2020. The decision had an immediate impact on its shares, which dropped 4% in the aftermarket session on Dec 16, following the news.

What Led to the 737 Max Production Suspension?

In March, Boeing’s 737 Max planes were grounded for the first time following two fatal air crashes that killed a total of 346 people. As a result, more than 700 737 Max planes were grounded worldwide, back then. To make matters worse, the production rate for the 737 Max had to be reduced from 52 per month to 42, in the following month.

Later during the year, Boeing's 737 was once again under scrutiny as problems this time emerged in the form of manufacturing defects in slat track assemblies on some of its 737 airplanes. Per the Federal Aviation Administration (FAA), 179 Max aircraft were affected worldwide.

The decision to suspend production is also driven by several other factors, including the extension of certification into 2020, and the timing uncertainty regarding returning to service and obtaining global training approvals. All the aforementioned issues along with other problems have led to a constant conflict between Boeing and international air-safety authorities, which repeatedly delayed the return of 737 Max fleet to service.

Ultimately, it came down to Boeing temporarily suspending the production of the grounded 737 Max aircraft after the FAA announced that it would not approve the plane’s return to service before 2020.

Boeing’s Downfall is Airbus’ Gain

In June, matters worsened for Boeing, as it lost a mega deal to Airbus, after Saudi Arabian carrier Flyadeal made commitments to buy 50 A320 Neo jets replacing its $5.9 billion-agreement with Boeing inked last December for 737 Max 8 jets. Boeing, moreover, has not received any new orders for the past five months.

Per Airbus' (OTC:EADSY) recent monthly data, deliveries and new orders are well ahead of Boeing and will likely outpace the same in annual deliveries for the first time, since 2011. Such impressive delivery figures of its arch-rival positions Boeing at a relatively disadvantageous position in the commercial aerospace industry.

Entering into 2020, it looks like all issues pertaining to the Boeing 737 MAX might be good news for Airbus SE. As the A320 and the 737 variants are competitors in the same class of aircraft, the suspension of the 737 Max production may open the doors wide for Airbus to capture a larger share of the single-aisle commercial aircraft market.

Although Airbus is facing its own set of problems relating to the A320 neo production delays and other engine-related issues, we expect the gap between the Airbus A320 and the Boeing 737 to only expand, considering the latter’s prolonged misery with the 737 jets.

Price Performance

Ever since the second crash involving the 737 Max jet, shares of Boeing have lost 16% against the industry’s growth of 6.9%. On the other hand, shares of Airbus have witnessed 18.1% growth during the same time frame. This certainly reflects Boeing’s slowdown in the global aviation market and Airbus' reigning supremacy over the former.

Zacks Rank & Key Picks

Boeing currently carries a Zacks Rank #5 (Strong Sell).

A few better-ranked stocks in the same space are L3Harris Technology Inc (NYSE:LHX) and Leidos Holdings, Inc. (NYSE:LDOS) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

L3Harris’ long-term growth estimate currently stands at 8%. The company delivered average positive earnings surprise of 5.02% in the last four quarters.

Leidos Holdings delivered average four-quarter earnings beat of 8.93%. It currently has a solid long-term earnings growth rate of 7.5%.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>